X4 Pharmaceuticals
XFOR
96 hedge funds and large institutions have $143M invested in X4 Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 11 closing their positions.
76% more capital invested
Capital invested by funds: $81.2M → $143M (+$62M)
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
15% more call options, than puts
Call options by funds: $705K | Put options by funds: $611K
3% more funds holding
Funds holding: 93 → 96 (+3)
0.12% more ownership
Funds ownership: 1.93% → 2.04% (+0.12%)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.25M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$2.26M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$2.24M |
| 4 |
Morgan Stanley
New York
|
+$932K |
| 5 |
Goldman Sachs
New York
|
+$915K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.62M |
| 2 |
Millennium Management
New York
|
-$1.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$895K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$579K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$378K |
XFOR Hedge Fund Activity: Q1 2024 in Review
96 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2024, worth a combined $143M — up 76% from $81.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new XFOR positions and 11 closed out — a net gain of 3 holders — while 23 added to existing stakes and 24 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $4.25M. The largest seller was Armistice Capital, exiting entirely with an estimated $1.62M sold.
- 96 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2024, up from 93 in Q4 2023.
- Funds reported $143M of X4 Pharmaceuticals stock for Q1 2024, up 76% quarter-over-quarter.
- 14 funds opened new X4 Pharmaceuticals positions in Q1 2024 and 11 closed out, a net change of +3 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2024 was Soleus Capital Management, an estimated $4.25M added.
- The largest X4 Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $1.62M sold.
Based on aggregated 13F filings for Q1 2024.